ONCIN — Oncoinvent ASA Share News
0.000.00%
Last trade - 00:00- NOK305.43m
- NOK200.69m
- NOK28.07m
Brief: Acceptable Safety At Highest Dose Tested In Bergenbio's Phase 1B Study Confirmed
Brief: Bergenbio Says It Continues Work Towards Upcoming Milestones
Brief: Bergenbio Q1 Operating Expenses at NOK 39.9 Million
Brief: Bergenbio Announces NCI Clinical Collaboration With UT Health San Antonio And SOBI
Brief: Bergenbio Secures Underwriting Of Nok 118 Mln Gross Proceeds
Brief: BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation
Brief: Bergenbio Announces Initiation Of Phase 2A In First Line Non-Small Lung Cancer Patients With A Stk11 Mutation
Brief: Bergenbio Q4 Operating Expenses NOK 43.9 Million
Brief: Bergenbio Q3 EBIT NOK -28.1 Million
Brief: Bergenbio Q2 Operating Expenses at NOK 47.8 Million
Brief: Bergenbio Q1 Operating Loss Narrows To NOK 72.4 Mln
Brief: Bergenbio Q1 Operating Expenses at NOK 72.4 Million
Brief: Bergenbio Announces Data From Bemcentinib Trial In Mesothelioma Presented At Asco
Brief: Bergenbio Announces Terms Of Partially Underwritten Rights Issue
Brief: Bergenbio Proposes Partially Underwritten Rights Issue To Raise Up To NOK 250 Mln
Brief: Bergenbio Q4 Operating Loss NOK 76.4 Million
Brief: Bergenbio Announces Positive Data From Phase 2 Trial
Brief: Bergenbio Q3 Operating Loss Falls To NOK 62.4 Million
Brief: Bergenbio Secures Nok 100 Mln Loan Facility From Meteva